Epalrestat

DB15293InvestigationalSmall molecule

Epalrestat is under investigation in clinical trial NCT03244358 (Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer).

Mechanism: Pharmacologically active on Aldo-keto reductase family 1 member B1
Curator reviewed
Formula / weight: C₁₅H₁₃NO₃S₂ · 319.39 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyCHNUOJQWGUIOLD-NFZZJPOKSA-NSMILESC\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/C1=CC=CC=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Epalrestat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.